A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma

This study has been completed.

Sponsor:

Collaborator:

Pfizer

Information provided by:

Nycomed: A Takeda Company

ClinicalTrials.gov Identifier:

NCT01365533

First received: May 30, 2011

Last updated: May 4, 2012

Last verified: May 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	July 2005
Primary Completion Date:	July 2005 (Final data collection date for primary outcome measure)

No publications provided by Nycomed: A Takeda Company

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, Côté J, Duong M, Killian KJ, Milot J, Deschesnes F, Strinich T, Watson RM, Bredenbröker D, O'Byrne PM. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res. 2011 Oct 26;12:140.

To Top